search
Back to results

Vitamin D to Reduce Colds and Asthma Attacks in Young Children (DIVA-pilot)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Vitamin D
daily vitamin D supplement
Placebo
Sponsored by
St. Justine's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring asthma, virus diseases, pediatric, RCT, steroid

Eligibility Criteria

1 Year - 5 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • children aged 1-5 years
  • physician-diagnosed asthma as per GINA guidelines
  • upper respiratory tract infections as the main asthma exacerbation trigger
  • ≥4 respiratory infections in the past 12 months
  • ≥1 exacerbation requiring rescue oral steroids in the past 6 months or ≥2 in the previous 12 months.

Exclusion Criteria:

  • extreme prematurity (<28 weeks gestation)
  • infants <12 months of age
  • breastfed infants with no vitamin D supplementation
  • recent (<1 year) immigrants from countries where rickets and malnutrition prevalent
  • other chronic respiratory disease (broncho-pulmonary dysplasia; cystic fibrosis)
  • endocrine disorder of calcium/ vitamin D metabolism
  • disorder/ disease with associated malabsorption (inflammatory bowel disease)
  • kidney/ liver disease
  • sickle cell anemia
  • medications known to interfere with bone metabolism/ vitamin D levels
  • vitamin D supplementation >1000 IU/ day in past 3 months
  • unable to attend medical visit in 3-4 months
  • plan to leave the province during the next 6 months.

Sites / Locations

  • CHU Sainte-Justine

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Vitamin D

Arm Description

bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).

Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).

Outcomes

Primary Outcome Measures

serum Vitamin D
mean change in serum vitamin D from baseline to 3 months

Secondary Outcome Measures

adequate serum vitamin D
difference in the proportion of children with serum vitamin D ≥75nmol/L at 3 months

Full Information

First Posted
November 25, 2013
Last Updated
January 8, 2015
Sponsor
St. Justine's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01999907
Brief Title
Vitamin D to Reduce Colds and Asthma Attacks in Young Children
Acronym
DIVA-pilot
Official Title
Vitamin D vs. Placebo in the Prevention of Viral-induced Exacerbations in Preschoolers With Asthma: a Pilot RCT
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Justine's Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Viral infections are the main cause of asthma attacks in preschoolers, an age group with the highest rate of emergency visits due to asthma. While high doses of inhaled or oral corticosteroids provide benefits, these have been associated with adverse outcomes. Most asthmatic children have lower blood levels of vitamin D compared to non-asthmatic children. Low vitamin D level has been linked to more frequent and more severe asthma attacks as well as with higher dose requirement of inhaled corticosteroid. Recent studies show that vitamin D supplements can reduce the number of asthma attacks triggered by viral infections in children. Unfortunately, most people forget to take vitamin D every day during the fall and winter season as recommended in Canada. A solution is to give a vitamin D bolus by mouth. This has been shown to safely and effectively increase vitamin D levels in children. The investigators hypothesise that a vitamin D bolus given in clinic will sufficiently increase the blood level of vitamin D to prevent the expected winter decline in vitamin D, compared with placebo in preschool-aged children with asthma. This six-month pilot randomized controlled trial aims to: (1) show that a vitamin D bolus is superior to placebo in raising vitamin D levels; (2) record the number of asthma attacks and viral infections in enrolled participants; and (3) identify problems that may call for protocol changes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
asthma, virus diseases, pediatric, RCT, steroid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
Arm Title
Vitamin D
Arm Type
Active Comparator
Arm Description
Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D
Other Intervention Name(s)
cholecalciferol
Intervention Description
100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
Intervention Type
Dietary Supplement
Intervention Name(s)
daily vitamin D supplement
Other Intervention Name(s)
cholecalciferol (Pediavit)
Intervention Description
Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
placebo given in a 2ml dose by mouth at baseline.
Primary Outcome Measure Information:
Title
serum Vitamin D
Description
mean change in serum vitamin D from baseline to 3 months
Time Frame
3 months
Secondary Outcome Measure Information:
Title
adequate serum vitamin D
Description
difference in the proportion of children with serum vitamin D ≥75nmol/L at 3 months
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
exacerbations requiring oral corticosteroids
Description
number of patients with one or more exacerbations requiring oral steroids, as documented by pharmacy dispensation records and medical records
Time Frame
6 months
Title
number of viral infections
Description
number of patients/person-month of observation documented two days parent-reported on the Canadian Acute Respiratory Illness and Flu Scale and Positive viral presence, determined by polymerase chain reaction on nasal sample
Time Frame
6 months
Title
Hypercalciuria
Description
urinary calcium: creatinine ratio >1.25 (1-2 years) and >1 (2-5 years) mmol/mmol
Time Frame
any point during the 6 months
Title
Cytokine/ chemokine profile
Description
change in serum cytokine/ chemokine profile from baseline to 10 days post-bolus dose
Time Frame
10 days
Title
duration of viral infections
Description
number of days with respiratory tract symptoms as reported on the parent completed Canadian Acute Respiratory Illness & Flu Scale
Time Frame
in the event of a cold during the 6 months
Title
severity of exacerbations
Description
area under the curve for β-agonist use as documented by parent of the 'Asthma Flare-Up Diary for Young Children'; need for hospital admission
Time Frame
in the event of an exacberbation during the 6 months
Title
duration of exacerbations
Description
Number of days with asthma symptoms as reported on the parent-reported 'Asthma Flare-Up Diary for Young Children'
Time Frame
in the event of an exacerbation during the 6 months
Title
participant retention
Description
percentage of patients retained until 6 months after randomization
Time Frame
6 months
Title
protocol adherence
Description
participant attendance to all 4 home and clinic visits percentage of patients with all 4 blood and urine tests collected percentage of analyzable viral nasal swabs returned.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: children aged 1-5 years physician-diagnosed asthma as per GINA guidelines upper respiratory tract infections as the main asthma exacerbation trigger ≥4 respiratory infections in the past 12 months ≥1 exacerbation requiring rescue oral steroids in the past 6 months or ≥2 in the previous 12 months. Exclusion Criteria: extreme prematurity (<28 weeks gestation) infants <12 months of age breastfed infants with no vitamin D supplementation recent (<1 year) immigrants from countries where rickets and malnutrition prevalent other chronic respiratory disease (broncho-pulmonary dysplasia; cystic fibrosis) endocrine disorder of calcium/ vitamin D metabolism disorder/ disease with associated malabsorption (inflammatory bowel disease) kidney/ liver disease sickle cell anemia medications known to interfere with bone metabolism/ vitamin D levels vitamin D supplementation >1000 IU/ day in past 3 months unable to attend medical visit in 3-4 months plan to leave the province during the next 6 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francine M Ducharme
Organizational Affiliation
St. Justine's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Sainte-Justine
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3T 1C5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
33305842
Citation
Huey SL, Acharya N, Silver A, Sheni R, Yu EA, Pena-Rosas JP, Mehta S. Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD012875. doi: 10.1002/14651858.CD012875.pub2.
Results Reference
derived
PubMed Identifier
27456232
Citation
Jensen ME, Mailhot G, Alos N, Rousseau E, White JH, Khamessan A, Ducharme FM. Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): a pilot randomised controlled trial. Trials. 2016 Jul 26;17(1):353. doi: 10.1186/s13063-016-1483-1.
Results Reference
derived

Learn more about this trial

Vitamin D to Reduce Colds and Asthma Attacks in Young Children

We'll reach out to this number within 24 hrs